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ABSTRACT 
 Imatinib mesylate (imatinib) has been shown to be highly efficacious in the 
treatment of chronic myeloid leukemia (CML).  Continuous and adequate dosing is essential 
for optimal outcomes and with imatinib treatment possibly being life-long, patient 
adherence is critical.  The ADAGIO study aimed to assess prospectively over a 90-day period 
the prevalence of imatinib nonadherence in CML patients; to develop a multivariate 
canonical correlation model of how various determinants may be associated with various 
measures of nonadherence; and to examine whether treatment response is associated with 
adherence levels.  A total of 202 patients were recruited from 34 centers in Belgium, of 
whom 169 were evaluable.  One-third of patients were considered to be nonadherent.  Only 
14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken.  On 
average, patients with suboptimal response had significantly higher mean percentages of 
imatinib not taken (23.2%, SD=23.8) than did those with optimal response (7.3%, SD=19.3, 
P=0.005; percentages calculated as proportions x 100).   Nonadherence is more prevalent 
than patients, physicians, and family members believe it is, and therefore should be 
assessed routinely.  It is associated with poorer response to imatinib.  Several determinants 
may serve as alert signals, many of which are clinically modifiable. 
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Introduction 
 
 Imatinib mesylate (imatinib) is a major advance in the pharmacological treatment of 
chronic myeloid leukemia (CML) with regard to efficacy and safety
1
.  Imatinib blocks the 
ATP-binding site of the BCR-ABL tyrosine kinase with high selectivity
2
 and has been found 
effective in the chronic
3
 and accelerated phases of CML
4,5
, as well as in blast crisis
6
.  Long-
term follow-up studies have shown that imatinib’s therapeutic benefits, initially 
documented for up to 18 months
7
, may extend to seven years
8
 in continuously treated 
chronic phase CML patients. Imatinib 400mg daily has been recommended as first-line 
treatment for patients newly diagnosed in chronic phase of the disease
9
, in part also 
because of the impact on quality of life
10,11,12
 and favorable cost-efficacy
13
 and cost-
effectiveness 
12,14,15
 
 Continuous and adequate imatinib dosing is essential to achieve therapeutic 
outcomes.
16
  Hence, patient adherence, defined as the extent to which a person’s behavior 
corresponds with the agreed recommendations of a healthcare provider
17
, is critical.    
Though often trivialized as a patient problem, adherence behavior is influenced also by the 
clinician and the healthcare system, the disease and its treatment, and economic and social 
factors.
17
 
Retrospective analyses of claims data in the US provide some preliminary evidence 
about adherence to imatinib.  An analysis of 374 patients with CML and 91 patients with 
gastrointestinal stromal tumors (GIST) with at least 12 months of treatment found mean 
and median persistence rates across all patients of 69.4% and 79.7%, respectively (no 
disease-specific rates were reported).
18
  Another analysis reviewed 267 CML patients in 
their first year of treatment with imatinib.
19
   The mean medication possession ratio (MPR, 
defined as total days supply of imatinib divided by 365) in the first year was 77.7%.  MPR 
was lower among female patients, patients taking relatively more concomitant medications, 
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those with high cancer complexity, and those started on imatinib doses of 600mg/day or 
higher.  Female patients and those with high cancer complexity were about twice as likely to 
interrupt treatment.  In addition, 30.7% failed to refill imatinib within 30 days; however all 
patients with treatment interruptions resumed imatinib treatment within the 12-month 
period.   In both studies
18,19
 lower imatinib adherence was associated with higher medical 
expenditures.   
A case-control study evaluated the adherence (measured by pill count converted to 
mg taken / mg prescribed x 100) of 21 evaluable CML patients in their first year of imatinib 
treatment and its association with cytogenetic response.
20
  Patients were matched for sex, 
age, and hematologic response with controls from an existing database.  The mean 
adherence rate for the cases during the 12-month period was 96.1%±9%.  89.9%±20% of 
cases showed major cytogenetic response (defined as <35% Ph-positive metaphases) 
compared to 60%±25% for controls (for whom no adherence data were available).  Rates 
for complete cytogenetic response were not reported. 
 To our knowledge, no prospective studies of patient adherence with imatinib 
treatment have been published in full.  The ADAGIO study (Adherence Assessment with 
Glivec®: Indicators and Outcomes) aimed (1) to examine prospectively over a 90-day 
period, in the “real practice” setting, the prevalence of imatinib nonadherence in CML 
patients in Belgium on imatinib treatment for at least 30 days; (2) to develop a multivariate 
canonical correlation model of how various determinants may be associated with various 
measures of nonadherence; (3) and to examine whether treatment response is associated 
with adherence levels. 
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Patients and methods 
 
Design and sample 
 
 This study was designed as a prospective, observational, multi-center, 
noninterventional study with two time points: baseline (enrollment visit) and follow-up 
approximately 90 days later.   Eligible were male and female patients, at least 14 years old, 
diagnosed with CML, and on imatinib treatment within the approved label for at least 30 
days (to enable assessment of adherence prior to the observational period).  Excluded were 
patients with known sensitivity to imatinib, patients not treated within the approved label, 
and patients with a severe medical condition that in the view of the investigator prohibited 
participation in the study.  Patients were allowed to take other medications and to continue 
or discontinue these medications at any point in time during the study period as this was an 
observational study not intended to interfere with physicians’ clinical practice.  A total of 
202 patients were recruited by 51 physician-investigators at 34 centers in Belgium.  
 The study protocol was approved by the medical ethics committee of the University 
Hospital Gent (UZ Gent, Gent, Belgium) as well as the medical ethics committee at each 
participating center.  All patients gave written informed consent in accordance with the 
Helsinki protocol. 
 
Variables and measurement methods 
 
 Table 1 summarizes the variables included in this study.  The complete data model 
and English translations of the case record forms are available from the corresponding 
author. Major variables and measurement methods are specified below. 
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 Disease parameters.  Hematologic response was defined as complete response 
(leukocyte count <10x10
9
/L, platelet count <450x10
9
/L, <5% myelocytes plus 
metamyelocytes, no blasts or promyelocytes, no extramedullary involvement, and no CML 
accelerated phase or blast crisis), no evidence of leukemia, or return to chronic phase.  
Cytogenetic response in bone marrow cells was defined as complete (0% Ph-positive 
metaphases), partial (1-35% Ph-positive metaphases), or major (complete plus partial 
responses).  Molecular response was expressed as ≥3 and ≥2 log reductions in the BCR-
ABL/BCR ratio per local laboratory without standardization.  In accordance with the 
European LeukemiaNet criteria
9
 suboptimal response was defined at 3 months as 
incomplete hematologic response; at 6 months as less than partial cytogenetic response; 
and at 18 months as less than major molecular response and, in case of loss of major 
molecular response, other limitations or other chromosomal abnormalities.  
 
 Adherence.  The WHO definition of adherence, being the extent to which a person’s 
behavior corresponds with the agreed recommendations of a healthcare provider
17
, was 
operationalized along the behavioral dimensions of taking and timing adherence, 
occurrence of drug holiday(s), and/or reduction in dose of medication. 
  
Given the absence 
of a gold standard of adherence measurement
21,22
, the varying benefits and limitations of 
available methods
22
, and keeping clinical utility in mind, several methods were used to 
assess adherence.  This is congruent with the Osterborg and Blaschke
23
 recommendation to 
combine several assessment methods. 
  At both baseline and follow-up, physicians used the Basel Assessment of Adherence 
Scale with Immunosuppressive Medication
24
 adapted to imatinib.  This scale (referred to 
here as BAAS) is a 4-question clinical interview guide: a positive answer to any questions 
constitutes nonadherence. Physicians also used the BAAS to assess patient adherence as 
perceived by a third person such as spouse or other family member (as available).  
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Physicians, patients, and third persons rated patient adherence on a 10cm visual analogue 
scale (VAS) converted to a 0-100 score.  Adherence with scheduled appointments was 
measured as the ratio of appointments scheduled to appointments kept.  At follow-up, a pill 
count was performed and expressed as the percentage of imatinib taken to imatinib 
prescribed. 
 
 Patient scales.  At baseline, patients completed the Long-Term Medication Behavior 
Self-Efficacy scale (LMBSE).
25,26
  Self-efficacy refers to a person’s level of confidence in 
performing a specific behavior.
27
  The self-efficacy score is calculated by summing scores on 
all items divided by the number of items.  Self-efficacy scores thus range from 1 to 5, with 
higher scores indicating higher levels of self-efficacy.  At both baseline and follow-up, the 
Patient Assessment of Chronic Illness Care
28,29
 (PACIC) scale was used to measure patients’ 
perceptions of the degree of chronic care they received; and the SF-8 Health Survey
30
 
(nonstandardized) to assess functional status and quality of life.  Patients were also queried 
about their understanding of disease and treatment and their methods of information-
seeking.  Patients were asked to complete these scales at the time of the respective visit 
(Table 1).  To protect the confidentiality of their responses, completed instruments were 
returned in a sealed envelope to center staff. 
 
 Physician-investigator experience and perceptions.  At baseline physician-
investigators were queried, among other things, about the number of active CML patients 
seen in the past year and the median time they spend with newly diagnosed patients and 
patients in follow-up.  They were asked to rank-order various sources of information and 
modes of decision-making about managing CML, as well as various modes of patient 
interaction and support.  Physicians estimated the percentages of patients adherent with 
imatinib treatment in the first month following diagnosis and after one year; and the 
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percentage of imatinib-treated patients who do not achieve therapeutic effect because, and 
only because, of poor adherence.  Physicians also rated the relevance of several potential 
determinants of adherence behavior: patient demographic, social, and economic factors; 
patient-physician relationship; treatment; disease; physician; and other patient variables 
(knowledge, attitudes, and feelings about disease and treatment; participation in treatment; 
multiple comorbidities; lifestyle; and mental health).  Lastly, physicians rated the 
effectiveness, feasibility, cost, and clinical applicability of thirteen adherence-enhancing 
interventions. 
 
Statistical analysis 
 
 Prevalence was estimated as the period prevalence rate for the time period 
indicated, using the evaluable sample of patients as the denominator. 
 Considering that patients were “nested” under physicians and centers, 
unconditional hierarchical linear modeling (HLM) with estimation using residual maximum 
likelihood (REML) was applied to examine the class effects of physician or center.  The 
intraclass coefficient (ICC) quantifies the proportion of variability accounted for by the class 
being examined and was used to attribute the respective percentages of variance in 
continuous adherence measures to class (ICCx100) and patients ([1-ICC]x100).   
 To permit the use of a multivariate definition of nonadherence, canonical 
correlation analysis (CCA) was used to multivariately model the relationship of a vector 
composed of three complementary measures of nonadherence with a vector comprising 
patient- and physician-related determinants.  CCA has been termed the multivariate analog 
of multiple linear regression and accommodates two or more criterion (“dependent”) 
variables compared to the univariate limitation of one criterion variable in multiple linear 
regression.
31
  While one could construct a composite index of nonadherence as, for instance, 
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the (weighted) sum of the three variables included here, a multivariate representation as a 
vector enables consideration of all covariations among variables through the covariance 
matrix.  Thus it measures a total that is more than the sum of its parts.  The combination of 
different measurement methods in one vector is congruent with Osterberg’s and Blaschke’s 
recommendation.
23 
  A non-adherence vector was specified with the following elements: 
inverse patient VAS rating (self-perception), patient BAAS score (self-report), and inverse 
pill count.  Inversions were done so that VAS rating and pill count were expressed 
isodirectionally with the BAAS.  The statistical significance of canonical correlation 
coefficients derived was determined by Wilk’s test that remaining correlations are zero.  
Also calculated for the vector of determinants were the canonical loadings, the percent of 
variance explained, and the redundancy statistic.  The model was directional in that 
variability in the nonadherence vector was assumed to be a function of variability in the 
vector of determinants, hence the calculation and reporting of parameters for the latter 
vector. 
 For comparisons between two subgroups of patients classified on the basis of 
treatment response the t-test or its nonparametric analog (Mann-Whitney U) were used, 
with Bonferroni class corrections to manage multiplicity.  Baseline to follow-up 
comparisons were done using the paired t-test or its nonparametric analog (Wilcoxon 
signed-rank test).  Continuity corrections were applied in contingency table analyses of 2x2 
tables.  Associations between adherence and other variables were determined, depending 
on the levels of measurement of the variables involved, by means of the Pearson product 
moment correlation coefficient, the Spearman rho coefficient, or the point bi-serial 
coefficient. 
 For all statistical calculations, the significance level α was set at 0.05.  Using multiple 
power and precision calculations given the various objectives, required sample size 
estimates ranged from 126 to 162 evaluable patients to achieve power of 0.80 at α=0.05. 
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Results 
 
Patient characteristics 
 
 A total of 169 patients contributed by 51 physician-investigators at 34 centers 
completed the study with evaluable data.  Evaluable was defined as meeting inclusion 
criteria and having baseline and follow-up data (including the physician’s evaluation, 
patient interview and patient questionnaire), pill counts at end of study, and data on 
practice characteristics from the corresponding physician questionnaire.  All patients were 
required to have at least one of the outcome variables of physician-rated adherence or 
patient-rated adherence. Reasons for being considered non-evaluable included lack of 
baseline patient questionnaire (2.0%), follow-up patient questionnaire (6.4%), follow-up 
patient interview (0.5%), pill count (8.4%), or physician questionnaire (2.0%) as well as 
absence of both physician-rated and patient-rated adherence measure (8.4%). The 
evaluable sample size enabled estimation of parameters with adequate precision and 
permitted statistical analysis with power of at least 0.80 at α=0.05. 
The mean age was 57.2±14.5 years (Table 2).  The majority of patients were male 
(55.0%) and educated at lower or higher secondary school level (64.6%).  Virtually all 
patients were white (96.4%).  Most lived with family (78.7%), however 19.5% resided alone 
at home and a few (1.8%) in supportive care facilities. 
 The median and mean times from diagnosis of CML were 41.9 months and 
48.8±41.4 months, respectively (from 1.6 to 347 months; 95%CI 41.4 to 56.2); 45.1% were 
symptomatic at the time of diagnosis.  At baseline, almost all patients had primary CML 
disease (93.3%) and were in chronic phase (98.2%).  Hematologic, cytogenetic, and 
molecular responses were documented as available. There were 147 patients (87.0%) with 
a complete hematologic response, 7 (4.1%) had no evidence of leukemia (complete 
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hematological response with absolute neutrophil count >1000/mm
3
 and platelet count 
>20,000mm
3
), and none had returned to chronic phase (note, 8.9% had no documented 
hematologic response). Further, 129 patients (76.3%) had a cytogenetic response at 
baseline, including 110 (65.1%) with complete response. There were 47.9% of patients who 
had a ≥3 log reduction in BCR-ABL/BCR ratio and 13.6% showing ≥2 log reduction (another 
38.5% had no documented molecular response). These parameter proportions did not 
change in a statistically significant manner from baseline to follow-up (Table 3). 
 Most common prior CML treatments included interferon (64.2% of patients; of 
these, 28.0% experienced treatment failure and 13.0% relapsed, i.e., loss of response, 
following initial treatment success) and hydroxycarbamide (77.1%; treatment failure rate 
was 40.3%, relapse rate 27.4%); 54.4% of patients had received both prior to imatinib 
treatment.  For 14.8% of patients imatinib was the first line of treatment.  The median and 
mean duration of exposure to imatinib were 35.2 and 32.9±19.8 months respectively (from 
1.0 to 72.8 months; 95%CI 29.8 to 36.1).  There were minimal, statistically not significant 
differences in the mean imatinib dosages at initiation of treatment, start of study, and 
follow-up.  With the exception of 9.5% of patients taking paracetamol, no patients were 
prescribed any other agents known to interact with imatinib.   
 Most frequent (in ≥15% of patients) past or current comorbidities were 
gastrointestinal (28.4%), skeletal (26.6%), cardiac (22.5%), and endocrine/metabolic 
disease (16.0%).  About (40.8%) of patients had a history of smoking (incl. 10.9% active) 
and 32.7% a family history of cancer. 
 During the 90-day study period, imatinib dose was changed in seven (4.1%) and 
discontinued in three (1.8%) patients, mainly (70%) because of intolerance to the 
medication (Table 2). 
 
Patient-reported outcomes 
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At baseline, patients’ SF-8 scores for functional status and quality of life ranged from 14 to 
42 on a 8-42 nonstandardized scale (M=31.5, SD=6.5).  Patient ratings of the degree of 
chronic care (PACIC) received ranged from 1 to 5 on a 1-5 scale (M=2.8, SD=0.9).  Self-
efficacy of long-term medication behavior (LMBSE) ratings were between 1.8 and 5 on a 1-5 
scale (M=4.7, SD=0.5).  Patient’s knowledge of disease and treatment was observed across 
the full range of the 0-100 scale (M=71.9, SD=20.3) (Tables 2 and 3).  There were no 
statistically significant changes from baseline to follow-up for functional status/quality of 
life and knowledge of disease and treatment. Patients’ perceptions of chronic care 
decreased from baseline to follow-up (p = 0.01).  
 
Physician variables 
 
 Physician-investigators ranged in age from 29 to 65 years (M=44.5±8.0) and had 
been practicing medicine between 4 and 35 years (M=17.7±8.1).  Most were male (59.2%); 
74.0% were hematologists versus 26.0% oncologists; working in university (46.9%), 
university-affiliated (18.4%), or non-university hospitals (34.7%).  They had seen between 
1 and 50 active CML patients in the 12 months preceding the start of the study 
(M=10.7±8.8); spending between 30 and 100 minutes on the first visit with a newly 
diagnosed CML patient (M=43.9 =±15.3) and between 10 and 30 minutes on treatment 
follow-up visits (M=20.2±5.8). 
 When asked to rate various strategies to enhance patients’ involvement in the 
management of their disease, the modal ratings were, in descending order, encouraging 
patients to phone with questions (modal rating of 4 out of 5 by 51.0% of physicians), 
explaining the importance of treatment adherence (mode=3; 45.1%), talking to the patient 
about medication dosing and side effects (mode=2; 45.1%) and talking to the patient about 
 For personal use only. at BIOMEDISCHE BIBLIOTHEEK on May 10, 2009. www.bloodjournal.orgFrom 
Page 13 
 
the disease process (mode=1; 52.9%).  Hand-outs and related patient materials received 
modal ratings of 0, whether self-developed materials (80.4%), materials designed by 
pharmaceutical companies (60.8%), or received at a continuing medical education event 
(54.9%). 
 Physicians believed that on average 92.8±13.1% (range=20-100) of patients were 
imatinib adherent in the first month after diagnosis and that 87.4±9.4% (range=50-100) 
were so after one year of treatment.  They also reported that on average 8.0±6.4% (range 0-
30) of patients do not achieve therapeutic effect because, and only because, of poor 
treatment adherence. 
 Further, physicians were asked to rate the various WHO
17
 categories of factors that 
impact on adherence as “not”, “somewhat”, or “strongly contributing” to nonadherence to 
imatinib therapy.  We combined the latter two options to create a binary score of not 
contributing vs. contributing to nonadherence.  Therapy-related factors were identified by 
the most physicians as determinants of non-adherence (96.1% of respondents), followed by 
patient demographic, social and economic factors (92.1%), the patient-physician 
relationship (92.1%), disease-related factors (84.3%), physician-related factors (70.6%), 
and other patient-related variables (70.5%).  Within the patient-physician relationship, the 
communication and interpersonal style of the physician as well as the continuity of care by 
the physician were identified by most respondents as a contributing variable (both 96.1%), 
followed by time the physician spends with the patient (91.2%), physician empathy and 
assistance (89.2%), and patient involvement in planning (88.3%).  As to physician-related 
variables that contribute to patient adherence, most respondents endorsed practicing in 
accordance with (92.2%) and knowledge of practice guidelines (91.2%), and to a lesser 
extent years of clinical experience in general (66.7%)  and in treating patients with chronic 
disease (72.5%),  or the number of patients with chronic disease seen regularly in practice 
(66.7%). 
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 Physicians rated the effectiveness, feasibility, cost (all on a 0-3 scale) and clinical 
applicability (0-5 scale) of thirteen adherence-enhancing interventions (Table 4).  On 
average, the highest (mean ≥2) effectiveness, feasibility, and applicability ratings were given 
to improved patient-physician communication, patient education, simplifying the 
medication regimen, regular physician contact, spouse/family involvement, and monitoring 
of patient adherence by the physician; most of which were rated as low to medium cost.  
 
Patient adherence with imatinib therapy 
 
 In general, VAS ratings of patient adherence by physicians, patients, and third 
persons (if available) were very high (94.9 to 97.1 on 0-100 scale) at both baseline and 
follow-up.  Differences within source over time were statistically not significant, and neither 
were differences between sources within time point. 
 Per the BAAS, 36.1% of patients at baseline and 32.7% at follow-up reported to have 
exhibited at least one of the four queried behaviors in the 4 weeks prior (P=ns).  The most 
common behaviors were occasionally not taking a dose (16.1% at baseline, 13.3% at follow-
up) and taking a dose with a delay of more than two hours (22.2% and 25.3%, respectively). 
 For those patients with scheduled appointments, 89.4% had kept those 
appointments in the 30 days prior to baseline and 86.6% during the 90-day study period.  
At baseline, mean percentage of appointments kept was 90.9%±28.6; at follow-up this was 
92.1%±20.1 (P=ns). 
 Pill counts were used to calculate the percent of total prescribed dose taken to 
prescribed during the 90-day period.  Scores ranged from 29% to 202% of prescribed dose 
(M=90.9±20.1). 
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Association of adherence with length of illness, duration of imatinib treatment, and safety 
and tolerance 
 
 We examined the associations of time since CML diagnosis, time on imatinib 
treatment, number of adverse events (general and suspected to be related to imatinib), and 
number of patient-reported symptoms and their bothersomeness with adherence at both 
enrollment (physician, patient, and third person VAS; BAAS) and at follow-up (physician, 
patient, and third person VAS; BAAS; pill count).  There were no significant associations 
between adherence behavior and length of illness or duration of treatment at either 
enrollment or follow-up.   With the exception of a weak correlation (r
bs
=-0.240, P=0.007) 
between bothersomeness of symptoms and adherence behavior per the BAAS, all other 
associations of safety and tolerance variables with adherence (VAS and BAAS) were 
statistically not significant at enrollment.  At follow-up, there were no statistically 
significant associations of general adverse events, imatinib-specific adverse events, number 
of patient-reported symptoms, and bothersomeness of these symptoms with pill count 
adherence.  Weak correlations were observed between the number of adverse events and 
patient (r=0.166, P=0.032) and third person (r=0.237, P=0.045) perceptions of adherence 
(per VAS scales), and adherence behavior (r
bs
=-0.241, P=0.002); and between the number of 
symptoms reported by patients and their perceptions of (r=0.208, P=0.007) and actual 
adherence behavior (r
bs
=-0,211, P=0.006). 
 
Multivariate analyses 
 
 Though above we report adherence results for all measures, only those with data for 
at least 160 patients were included in multivariate analyses. 
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 Attribution of variance in adherence behavior.  The ICCs for physician and center for 
patient VAS adherence ratings were 0.346 and 0.362, respectively.  For physician VAS 
adherence rating, the ICCs for physician and center were 0.069 and 0.120.  Physician ICC for 
pill count was 0.091; the center ICC for this adherence parameter was <0.01.  Physician and 
center ICCs for the BAAS were 0.072 and 0.122. 
 
 Canonical correlation modeling.  A model including 12 patient-related and 6 
physician-related determinants with either a negative or positive influence on non-
adherence was fitted (Table 6).  The canonical correlation was 0.509 (Wilk’s=0.484, 
P=0.036).  The model had minimal redundancy (0.015).  Patient-related determinants 
associated with higher nonadherence were, in descending order of canonical loading: 
higher age (0.649), longer time since CML diagnosis (0.272), living alone (0.246), male 
gender (0.194), longer time on imatinib (0.193), imatinib dose ≥600mg/day (0.193), higher 
degrees of chronic care received (0.125), and higher self-reported functional status and 
quality of life (0.117).  Physician-related determinants of higher nonadherence included 
median duration of treatment follow-up visits (0.237; presumably a proxy of vigilance) and 
years of professional experience (0.135). 
 On the other hand, patient-related variables associated with better adherence (i.e., 
lower nonadherence) were knowledge of disease and treatment (−0.314), more 
medications to be taken daily (−0.184), secondary school or higher education (−0.140), and 
self-efficacy in long-term medication behavior (−0.062).  Physician-related variables 
associated with a reduction in nonadherence included the number of active CML patients 
seen in the past year (−0.363) and the median duration of the first visit with a newly 
diagnosed CML patient (−0.119); and to a lesser extent, practicing in a university or 
teaching hospital (−0.003) and holding specialization in hematology (-0.002).  
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Nonadherence and treatment response 
 
 The nonadherence measure of pill count (expressed as percent not taken of percent 
prescribed) for the 90-day observational period was found to differentiate between various 
levels of treatment response recorded at study entry (Table 7).  On average, patients with 
suboptimal response had significantly higher mean percentages of imatinib not taken 
(23.2%±23.8) than did those with optimal response (7.3%±19.3, P=0.005; percentages 
calculated as proportions x 100).  Among patients treated with imatinib ≥12 months, those 
with complete cytogenetic response had significantly lower mean percentages of imatinib 
not taken (M=9.0%±18.6) than those with incomplete cytogenetic response 
(M=26.0%±24.4, P=0.012), a treatment result also observed in all patients regardless of 
length of treatment (M=9.1%±18.1 vs. M=23.9%±19.2, P=0.004).  No significant differences 
in mean percentages of pill count were observed for complete vs. incomplete hematologic 
response, major vs. less than major molecular response - in all patients and in those treated 
for 18 or more months.  There were no significant differences between response groups in 
the subjective measures of nonadherence (physician and patient VAS ratings) and 
adherence with scheduled appointments. 
 
Discussion 
 
 While general perceptions of patient adherence to imatinib were uniformly very 
high among patients, physicians, and third persons, and most patients kept their clinic 
appointments as scheduled, other measures showed a significant pattern of imatinib 
nonadherence among CML patients.    Using the 4-question BAAS, a clinically useful tool for 
rapid assessment of potential nonadherence, about one-third of patients qualified as 
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nonadherent in the thirty days prior to study enrollment and over the 90-day study period.  
The percentage of prescribed imatinib taken averaged 90.9 percent with 71.0% of patients 
taking less (down to 29%) but also 14.8% taking more than prescribed (up to 202%).  Only 
14.2% were perfectly adherent with 100% of prescribed imatinib taken.   
 Based on self-report and pill count, this sample exhibited higher nonadherence than 
reported in a meta-analysis of 569 studies across 17 diseases (24.8%), including 65 studies 
in cancer (79.1%).
32
  This is surprising because of the severity of CML as a disease, the high 
efficacy of imatinib, its tolerability profile relative to other antineoplastic agents, the high 
morbidity and mortality of CML prior to the advent of imatinib, and the convenience of oral 
administration.  These factors should be convincing reasons for CML patients to be highly 
adherent.  In general, adherence reduces the risk for null or poor treatment outcomes by 
26%, and adherent patients are three times as probable to have good treatment outcomes 
compared to nonadherent patients.
33
    
 Apart from a few low but statistically significant correlation coefficients, there was 
virtually no systematic relationship between adherence to imatinib and time since CML 
diagnosis, length of imatinib treatment, adverse events (general and suspected to be linked 
to imatinib), and patient-reported symptoms and their bothersomeness.  These findings 
may run counter to evidence in several other therapeutic areas
17,23,32,33
, however severity of 
disease, criticality of treatment, and clinical consequences of nonadherence should be taken 
into account.  In this regard, CML patients may be comparable to transplant patients in that 
there is limited forgiveness of nonadherent behavior and (slight) deviations from the 
prescribed regimen are associated with poorer clinical outcomes.  Where weak significant 
correlations where observed at follow-up, higher frequencies of general adverse events or 
greater number of patient-reported symptoms led especially patients to perceive 
themselves as more adherent - when in fact their actual nonadherence behavior declined.  
This suggests that assessment of patients’ adherence behavior is more important than their 
 For personal use only. at BIOMEDISCHE BIBLIOTHEEK on May 10, 2009. www.bloodjournal.orgFrom 
Page 19 
 
(already elevated) self-perceptions of adherence.  Importantly, how long patients have been 
diagnosed with CML or how long they have been treated with imatinib was not associated 
with either perceptions of or actual adherence behavior.  This is important because, 
clinically, one might expect (some) patients to be highly adherent at the beginning of their 
imatinib treatment but become less so after having been told that they had responded well 
to treatment.  Instead, how adherent a patient is to imatinib may be a stable behavior trait 
of that patient, rather than one fluctuating with treatment success – though this remains to 
be studied further. 
 Nonadherence may be a function of the patient, his/her treating physician, and the 
center where he/she is being seen.  Physician and center accounted for over a third of the 
variance in patient’s self-perceived adherence.  This attests to the importance of the patient-
physician relationship and patients’ positive appraisal of the treatment center.  Patients’ 
self-perceived (though inflated) adherence behavior may be an indication in itself of their 
willingness to actively participate in their care and their self-confidence in doing so.  The 
high adherence with scheduled appointments further underscores this link between 
patient, physician, and center.  The variance explained by physician and center in 
physicians’ subjective perception of patient adherence was much more modest (6.9% and 
12.0%, respectively); suggesting that for the most part physicians evaluate CML patients’ 
imatinib adherence on a case-by-case basis.  Similarly, the modest (9.1%) amount of 
variance attributable to treating physicians and the virtually zero percent for center, 
reinforces the importance of the patient-physician relationship.  
 Neither perceived adherence rates, self-reported adherence behaviors, nor 
adherence to scheduled appointments changed significantly over the 90-day study period – 
despite patients’ presumably knowing they were participating in an adherence study having 
given informed consent to such.  The high VAS ratings at baseline and follow-up may reflect 
in part a trend to overestimate adherence by virtue of being enrolled in an adherence study 
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or by social desirability bias
37
 to report the presumably correct behavior.  However, that 
rates for self-reported nonadherence behaviors and keeping scheduled appointments did 
not change over the 90-day period may suggest that imatinib adherence may be a rather 
stable behavioral trait minimally affected by time or participation in an adherence study. 
 Congruent with the recommendation for combining adherence assessment 
methods,
23 
we combined patient self-perceptions, nonadherence behaviors reported by 
patients, and pill count into a vector of nonadherence.  Canonical correlation modeling 
identified several variables associated with increased nonadherence as well as several 
variables with a mitigating effect on nonadherence; and this at both the patient and 
physician levels.  Note that these are not independent factors and should be interpreted as 
part of a canonical model of multiple complementary variables.  Demographic variables 
linked to nonadherence were patients’ age, living alone, and being male.  Also tied to 
nonadherence within the context of a multivariate model were length of time since the 
diagnosis of CML was made and how long patients had been treated with imatinib (although 
no univariate statistically significant correlations were observed).  This suggests that 
chronicity of disease and length of treatment may lead some patients to become more lax in 
their medication behavior.  Patients who function relatively well and perceive their chronic 
care more positively are also more likely to be nonadherent.  The association of 
nonadherence with imatinib dosing of 600mg/day or higher may be due to the various 
regimens for this dose: 1 tablet of 400mg in the morning and 2 capsules of 100mg in the 
evening, or 3 capsules of 100mg in the morning and in the evening. On the other hand, being 
more knowledgeable about disease and treatment, showing greater self-efficacy in long-
term medication behavior, and having at least a secondary school education are all 
associated with better adherence behavior.  Having to take more medications on a daily 
basis is also associated with imatinib adherence.  This is inconsistent with past findings in 
other therapeutic areas that the prescribed number of daily doses is inversely related to 
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adherence.
34
  Again, severity of disease, criticality of treatment, and seriousness of the 
clinical consequences of nonadherence may explain our finding.   Knowledge and self-
efficacy are clinically modifiable factors. 
 Physicians’ experience, practice patterns, and practice environment were found to 
influence adherence as well.  Shorter follow-up visits and years of practicing medicine were 
associated with increased nonadherence.  In contrast, an active CML practice, spending 
more time with patients at the time of diagnosis, and practicing as a hematologist in a 
teaching hospital were all related to better adherence.  
 Doti and colleagues
20 
reported a major cytogenetic response rate (0-35% Ph-
positive metaphases) of 89.9% but did not provide a breakdown in terms of complete 
versus partial response.  Our findings link the percentage of prescribed imatinib not taken 
to complete vs. partial cytogenetic response and optimal vs. suboptimal treatment response.  
On average, patients with a lesser response had taken between 74.0% and 76.8% of 
prescribed dose, compared to 89.9% and 92.7% for patients with a better response.  This 
constitutes strong initial evidence that nonadherence to imatinib treatment is associated 
with poorer treatment outcomes, and that 100% adherence with imatinib treatment is an 
essential clinical target.  
 Physicians rated the utility and applicability of thirteen adherence-enhancing 
strategies higher if these strategies involved active physician participation and/or decision-
making. Strategies requiring significant patient involvement, whether behaviorally or 
through the use of assistive devices were perceived as less helpful and applicable in clinical 
practice.  The critical role of patient education was recognized.  However, a meta-analysis of 
adherence-enhancing interventions found that the average effect size of interventions 
combining educational and behavioral strategies was 0.35 versus 0.20 for educational and 
0.22 for behavioral strategies alone.
35
  To improve adherence to imatinib, it will be 
important to challenge physicians’ current beliefs and practices and to develop integrated, 
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yet clinically and financially feasible, intervention models.  A more pragmatic view on and 
approach to imatinib nonadherence may also lead to more realistic perceptions of patient 
adherence and make physicians more aware of the problem. 
 Adherence behavior, not necessarily perceptions, should be assessed routinely 
throughout the care of CML patients.  Preferably, this should be done as part of the clinical 
interview and patient questioning should be nonjudgmental and nonaccusatory.  If needed, 
a short interview schedule as the BAAS can serve as a reminder to the clinician of the key 
questions to be used.  If a clinician suspects nonadherence but the patient denies so, 
additional direct (e.g., assay) and/or indirect methods (e.g., third person report, pill count, 
prescription refills, electronic monitoring) should be used.
23
  Generally, combined methods 
have been shown to have greater specificity.
36
 
 Nonadherence should be examined as a possible reason for patient non- or reduced 
response to imatinib before considering such patients to be imatinib-resistant and 
switching them to next-line treatment with the new second-generation tyrosine kinase 
inhibitors.  Nonadherence to imatinib must be ruled out as a possible cause of lack of 
optimal response. 
 Our study has several limitations and identifies areas for future research.  Of the 202 
patients, 169 (83.7%) had evaluable data at the follow-up visit, slightly higher than a 
recently completed cross-sectional study on adherence to glaucoma treatment conducted in 
Belgium as well (80.2%).
37
  This may have introduced a selection bias towards patients with 
better adherence, who can be expected to have more complete data than their nonevaluable 
counterparts.  Patient loss and missing date are not uncommon in observational studies.  
Relatedly, baseline and follow-up data for cytogenetic and in particular molecular response 
were censored.  The possible bias of good responders to treatment not being tested as 
frequently as poor responders cannot be excluded.  Though adequate for its intent to 
determine the prevalence of nonadherence, multivariately model determinants, and 
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compare the adherence behaviors of patients with better and those with lesser response to 
treatment, this study’s findings must be confirmed and extended in terms of sample size, 
duration of observation, methods of assessment of nonadherence, and modeling of 
treatment response as a function of patient-, physician-, and center-level determinants.  In 
the absence of clinically meaningful and empirically validated cut-off to infer nonadherence, 
all adherence measures except the BAAS were used as continuous variables.  Future 
research should explore meaningful cut-offs for self-reports, pill counts, and VAS ratings for 
the disease/drug dyad of CML/imatinib.  This could be achieved by studying the impact of 
nonadherence prospectively from both subclinical
38
 and clinical perspectives.  This study 
was limited to one country, for which, in addition, no registry data on the prevalence and 
incidence of CML are available (informally, the prevalence is estimated at 1000 patients in a 
total population of 10 million, hence this study captured approximately 1 in 6 CML patients 
in Belgium).  Involving additional countries may have the dual benefit of accruing more 
patients while better understanding variability in adherence behavior as a function of 
factors at the healthcare system level.  The BAAS may be a helpful tool to assess 
nonadherence in routine clinical practice.  However, in the absence of a validated version 
for CML, the version used in the ADAGIO study included the two hour deviation of the 
original immunosuppression version of the scale.  This may not be relevant considering the 
relatively long half-life of imatinib.  An appropriately revised version needs to be validated.   
Future research should complement indirect measures of adherence with direct measures; 
e.g., imatinib plasma level assays.
39
 The link between nonadherence and cytogenetic 
response needs to be elucidated further.  Our study was limited to 90 days, and it will be 
necessary to conduct prospective studies to map patterns of medication behavior and their 
impact on treatment outcomes over longer periods of time, especially for patients with a 
projected life-long dependence on imatinib.  This may also further clarify whether 
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adherence to imatinib treatment is a relatively stable behavior trait, or whether there is 
variability medium and long term over the course of disease and treatment. 
 To our knowledge, ADAGIO is the first published study of the prevalence, 
determinants, and clinical outcomes of nonadherence to imatinib treatment in patients with 
CML.  Nonadherence is more prevalent than patients, physicians, and third persons such as 
spouses and family members believe it is, and is related to poorer rates of response to 
imatinib.  Several determinants may serve as alert signals, while others are clinically 
modifiable.  Patients need to be assessed carefully in terms of their medication behavior and 
effective yet clinically feasible and cost-effective interventions need to be designed, studied, 
and implemented. 
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Table 1. Evaluation and Visit Schedule 
  visit 1 2 
  month 0 3 
Patient Characteristics   
 Sociodemographic data X  
 Medical history & current comorbidity X  
    
Disease-related Information   
 Disease history X  
 Current clinical status X X 
    
Concomitant medications    
 Medications: risk for Rx-Rx interactions X X 
    
Physician Variables   
 Sociodemographic data X  
 Education X  
 Specialty X  
 Practice environment X  
 Number of active CML patients X  
 Time spent with patients: newly diagnosed (first consultation) X  
 Time spent with patients: during treatment X  
 Use of scientific information / evidence-based practice X  
 Use of patient awareness and support materials X  
 Perspectives on patient compliance X  
    
Patient Compliance   
 
Basel Assessment of Adherence Scale, Visual Analog Scale - 30 days retrospective - patient 
interview X X 
 
Basel Assessment of Adherence Scale, Visual Analog Scale - 30 days retrospective – family member 
interview X X 
 Pill count (delta grams taken vs. grams prescribed) - 90 days retrospective  X 
 Appointment noncompliance - 30 days retrospective X X 
 Physician Visual Analog Scale rating of patient compliance - 30 days retrospective X X 
    
Patient Variables   
 Long-Term Medication Behavior Self-Efficacy Scale (adapted for CML/imatinib) X  
 Patient Assessment of Chronic Illness Care (PACIC) – 30 days retrospective X X 
 Symptom experience and distress – 30 days retrospective X X 
 Understanding of disease and treatment X X 
 Functional status / Quality of Life (SF-8) - 30 days retrospective X X 
 Patient knowledge-seeking behavior - 90 days retrospective  X 
    
Response Parameters   
 CML: hematological response, cytogenetic response, molecular response X X 
    
Treatment-related   
 Number of visits to GP between visit 1 and visit 2 related to CML/imatinib  X 
 Number of visits to specialist between visit 1 and visit 2 related to CML/imatinib  X 
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Table 2. Patient Demographics and Clinical Status at Baseline 
Patient Demographics
 
Age (range; M ± SD) 17-86; 57.2 ± 14.5 yrs 
Gender Male 55.0 % 
 Female 45.0 % 
Race White 96.4 % 
 Non-white 3.6 % 
Secondary school or higher education 55.5% 
Living at home alone  19.5 % 
History of CML and Treatment 
Years since CML Diagnosis (range; M ± SD) 0-29; 4.7 ± 4.4 yrs 
Symptomatic at diagnosis 
45.1 % 
Prior CML treatments and outcome Interferon                 64.2%  -  of which:  
 failure 28.0 % 
 not tolerated 59.0 % 
 success but relapse* 13.0 % 
 Hydroxycarbamide  77.1%  -  of which:  
 failure 40.3% 
 not tolerated 32.3 % 
 success but relapse 27.4 % 
 
Transplantation         1.8%  -  of which: 
 
 failure 0.0 % 
 not tolerated 0.0 % 
 success but relapse 100.0 % 
Current CML Status 
Disease status Primary 93.3 % 
 Relapse 6.7 % 
Disease phase Chronic phase 98.2 % 
 Accelerated phase 1.8 % 
 Blast crisis 0.0 % 
Current disease parameters Too early to judge 11.1 % 
 Available (see Parameters below) 88.9 % 
Parameters (if available)   
     Hematologic response Complete 87.0 % 
 
No evidence of leukemia 
4.1 % 
 
Return to chronic phase 
0.0 % 
 
Not documented 
8.9 % 
     Cytogenetic response 
Complete 
         65.1 % 
 
Major 
5.3 % 
 
Partial 
5.9 % 
 
Not documented 
23.7 % 
     Molecular response  
      
≥ 3 log 
47.9 % 
≥ 2 log 
13.6 % 
 
Not documented 
38.5 % 
Imatinib Treatment (range; M ± SD) 
Months on imatinib therapy at baseline  1.0-72.8; 32.9 ± 19.8 
Starting dose (mg/day) 100-800; 395.2 ± 77.9 
Baseline dose (mg/day)   100-800; 429.0 ± 106.2 
Follow-up dose (mg/day)  100-800; 420.1 ± 120.0 
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Number of patients in whom imatinib treatment changed between baseline and follow-up 
     Imatinib dose change 
 
7  
to 100 mg/day 1 
 300 mg/day 2 
 400 mg/day 3 
 600 mg/day 1 
     because of intolerance 6 
 suboptimal response 1 
     Imatinib discontinued  3 
     because of intolerance 1 
 progressive disease 2 
Patient-Reported Variables (range; M ± SD) 
Functional status / quality of life (8-42) 14-42; 31.5 ± 6.5 
Quality of chronic care (1-5) 1-5; 2.8 ± 0.9 
Long-term medication behavior self-efficacy (1-5) 1-5; 4.7 ± 0.5 
Knowledge of disease and treatment (0-100) 0-100; 71.9 ± 20.3 
Comorbidities Past Current 
Cardiac 11.8 % 12.4 % 
Vascular 7.1 % 4.1 % 
Pulmonary 8.3 % 4.1 % 
Renal 3.0 % 1.2 % 
Hepatic 1.8 % 1.2 % 
Neurologic 6.5 % 3.0 % 
Endocrine/Metabolic 7.7 % 10.7 % 
Muscular 2.4 % 0.6 % 
Skeletal 18.9 % 8.9 % 
Skin/Connective tissue 6.5 % 1.2 % 
Gastrointestinal 26.0 % 4.7 % 
Genitourinary 10.1 % 1.8 % 
Hematologic (except CML) 3.0 % 0.0 % 
Concomitant Medications 
Paracetamol 9.5 % 
Medication burden on typical day  Range Q1 Mdn Q3
# drugs taken per day  1-11 1 2 4
# times per day drugs are taken  1-5 1 2 3 
# medication units taken per day 
 1-18 3 4 6
* relapse = loss of response 
M = mean; SD = standard deviation; Q1 = 25
th
 percentile; Mdn = median = 50
th
 percentile; Q3 = 75
th
 percentile. 
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Table 3. Disease Phase, Disease Parameters and Patient-Reported Outcomes at Baseline 
and Follow-up 
 
Disease phase Baseline Follow-up P 
Chronic phase 98.2 % 99.4 % n.s. 
Accelerated phase 1.8 % 0.6 %  
Blast crisis 0.0 % 0.0 %  
Disease parameters (if available)* 
Hematologic response n=154 n=144 n.s. 
     Complete 95.5 % 94.4 %  
     No evidence of leukemia 4.5 % 2.8 %  
     Return to chronic phase 0.0 % 2.8 %  
Cytogenetic response n=129 n=110 n.s. 
     Complete 85.3 % 87.3 %  
     Major 7.0 % 6.4 %  
     Partial 7.8 % 6.4 %  
Molecular response n=104 n=96 n.s. 
     ≥ 3 log 77.9 % 75.0 %  
     ≥ 2 log 22.1 % 25.0 %  
 
Baseline Follow-up P 
 
Range M SD Range M SD 
 
Functional status / quality of life (8-42)** 14-42 31.5    6.5 16-42 32.3    6.5 n.s. 
Quality of chronic care (1-5) 1-5 2.8    0.9 1-4.9 2.6 0.9 0.01 
Knowledge (0-100) 0-100 71.9    20.3 0-100 69.2 24.4 n.s. 
*Valid % shown, missing data not reported. 
** Nonstandardized scores. 
M = mean; SD = standard deviation; P = probability of test statistic for test comparing baseline and follow-up; n = 
subsample size; n.s. = not significant 
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Table 4.  Physicians’ Perceptions of Utility and Applicability of Adherence-Enhancing 
Strategies 
Adherence-Enhancing 
Strategies 
Utility (0-3) 
Applicability 
in Practice (0-5) 
Effectiveness Feasibility Cost 
 M±SD M±SD M±SD M±SD 
Treatment selection based on 
patient characteristics 
1.9±1.1 1.6±1.1 1.3±1.0 1.0±1.5 
Patient education 2.6±0.6 2.1±0.8 1.4±0.8 3.1±1.9 
Improved patient-physician 
communication 
2.7±0.5 2.3±0.8 1.3±0.8 2.8±1.7 
Simplifying medication 
regimen 
2.5±0.7 2.3±0.7 1.6±0.9 2.3±1.9 
Self-monitoring of health 
status 
1.7±0.8 1.5±0.8 1.1±0.9 0.4±1.1 
Maintaining a health status 
diary 
1.7±0.8 1.5±0.8 1.0±0.8 0.5±1.3 
Memory cues 1.7±0.8 1.9±0.8 1.0±0.8 0.6±1.3 
Spouse / family involvement 2.2±0.9 2.0±0.9 0.6±0.8 1.3±1.4 
Regular physician contact 2.4±0.5 2.2±0.7 1.7±0.8 2.2±1.8 
Monitoring of patient 
compliance by physician 
2.2±0.7 1.8±0.9 1.4±0.8 0.7±1.1 
Electronic reminder system 1.5±0.9 1.2±0.8 2.3±0.9 0.3±1.1 
Electronic medication 
monitors 
1.6±0.9 1.3±0.7 2.3±0.9 0.3±1.1 
Providing rewards for good 
adherence 
1.4±1.0 1.3±0.8 1.8±0.9 0.5±1.4 
M = mean; SD = standard deviation 
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Table 5.  Adherence at Baseline and Follow-up 
Visual Analogue Scale  
Baseline Follow-up P
across 
Range        M            SD Range        M            SD  
Physician (N=167)  60-100     94.9          7.7 0-100       94.9          9.9 n.s. 
Patient (N=169) 25-100     95.3          8.5 75-100     95.7          6.1 n.s. 
Family (N=79) 80-100     97.0          5.0      75-100      97.1         5.4 n.s. 
P
down 
n.s. n.s.  
Basel Assessment of Adherence Scale 
% of patients (N=165) who in past 4 weeks… 
Dose not taken 16.1 % 13.3 % n.s. 
Consecutive doses not taken 3.0 % 1.8 % n.s. 
Dose taken with >2 hour delay 22.2 % 25.3 % n.s. 
Dose reduced 1.2 % 1.8 % n.s. 
% of nonadherent patients 36.1 % 32.7 % n.s. 
% of adherent patients 63.9 % 67.3 % n.s. 
Adherence with scheduled appointments (N=82)
1
 
% of adherent patients 89.4 % 86.6 % n.s. 
% of appointments kept (range, M ± SD) 0-100; 90.9 ± 28.6 0-150; 92.1 ± 28.8 n.s. 
Pill Count at follow-up (N=162) Range        M            SD  
% of prescribed dose taken from baseline to follow-up 29-202     90.9        20.1  
1 
Applies only to patients with scheduled appointments in 30 days prior to baseline and/or follow-up 
M = mean; SD = standard deviation; P
across
 = probability of test statistic for test comparing baseline and follow-up; 
P
down
 = probability of test statistic for test comparing within time point; N = sample size (available observations)
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Table 6.  Canonical Correlation Analysis of Set of Nonadherence 
Measures with Set of Determinants  
Determinants of  
Increased Nonadherence 
Canonical 
Loading 
Patient-related  
Age 0.649 
Months since diagnosis of CML 0.272 
Living alone 0.246 
Male gender 0.194 
Months on imatinib 0.193 
Imatinib dose ≥ 600mg/daily 0.193 
Quality of chronic care 0.125 
Functional status / quality of life* 0.117 
Physician-related  
Median duration of treatment follow-up visits 0.237 
Years of professional experience 0.135 
Determinants of  
Decreased Nonadherence 
Canonical 
Loading 
Patient-related  
Knowledge of disease and treatment - 0.314 
Number of medications taken per day - 0.184 
Secondary school graduate - 0.140 
Long-term medication behavior self-efficacy - 0.062 
Physician-related  
Number of CML patients seen in past year - 0. 363 
Median duration of first visit with newly diagnosed CML patient - 0.119 
Practicing in university or university-affiliated hospital - 0.003 
Hematologist - 0.002 
Canonical Model Parameters  
Canonical correlation 
     Wilk’s test = 0.484, χ
2
 = 74.04, P = 0.036 
0.509 
Redundancy proportion 0.015 
* nonstandardized scores 
χ
2
 = chi-squared test of goodness-of-fit; P = probability of test statistic for goodness-of-fit test 
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Table 7. Nonadherence (Pill Count) and Treatment Response 
 n M SD P 
All Patients     0.005 
Optimal Response 124 7.3% 19.3%  
Suboptimal Response 14 23.2% 23.8%  
Patients treated with Imatinib ≥ 12 months   0.012 
Complete Cytogenetic Response 98 9.0% 18.6%  
Incomplete Cytogenetic Response 9 26.0% 24.4%  
All Patients    0.004 
Complete Cytogenetic Response 109 9.1% 18.1%  
Incomplete Cytogenetic Response 15 23.9% 19.2%  
n = subsample sizes; M = mean; SD = standard deviation; P = probability to test statistic comparing 
response groups 
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